Key Points
- Insider sale: Janux Therapeutics insider Janeen Noel Doyle sold 4,059 shares at an average price of $14.03, totaling about $56,948. The transaction reduced her ownership by 5.07% and was made to cover tax withholding tied to vesting equity awards.
- Recent earnings beat: The company reported quarterly EPS of -$0.39, beating analyst expectations of -$0.52 by $0.13. However, revenue of $3.73 million came in below the $4.36 million estimate.
- Mixed Wall Street sentiment: Analysts currently rate Janux Therapeutics a Moderate Buy overall, with a consensus target price of $45.85. Recent price targets have been cut by firms like Guggenheim and Piper Sandler, while UBS downgraded the stock to neutral.
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider owned 75,941 shares of the company's stock, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Janux Therapeutics Price Performance
Shares of Janux Therapeutics stock opened at $13.76 on Friday. Janux Therapeutics, Inc. has a 1 year low of $12.12 and a 1 year high of $35.34. The company has a market capitalization of $839.08 million, a P/E ratio of -7.48 and a beta of 2.53. The business has a 50 day moving average price of $14.51 and a 200 day moving average price of $15.58.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. Guggenheim cut their price objective on Janux Therapeutics from $68.00 to $58.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Piper Sandler cut their price objective on Janux Therapeutics from $30.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Weiss Ratings upgraded Janux Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, April 22nd. Truist Financial upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Monday, May 4th. Finally, UBS Group downgraded Janux Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $45.85.
Get Our Latest Stock Report on Janux Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of JANX. AQR Capital Management LLC raised its holdings in Janux Therapeutics by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock valued at $262,000 after acquiring an additional 4,059 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Janux Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock valued at $583,000 after acquiring an additional 3,393 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Janux Therapeutics by 12.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock valued at $5,033,000 after acquiring an additional 20,657 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Janux Therapeutics by 82.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company's stock valued at $5,715,000 after acquiring an additional 112,116 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Janux Therapeutics by 12.0% in the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company's stock valued at $1,094,000 after acquiring an additional 5,055 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.
Janux Therapeutics Company Profile
(
Get Free Report)
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
